Sorrento Therapeutics Inc

Sorrento Therapeutics, Inc. engages in the research, development and manufacture of biopharmaceutical products. It focuses on therapies to treat specific stages in the evolution of cancer, from elimination, to equilibrium and escape which include biosimilars, immuno-oncology antibodies, cellular therapy, cell internalizing antibodies, and antibody drug conjugates. It operates through the Sorrento Therapeutics and Scilex segments. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.

SAN DIEGO, Oct.  15, 2019  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that a Los Angeles Superior Court judge has rejected Patrick Soon-Shiong’s attempt to allow him and his company, NantPharma, to avoid the billion-dollar fraud and breach of contract claims that Sorrento filed against them earlier this year.  Sorrento’s claims relate to the “catch and kill” scheme that Soon-Shiong allegedly orchestrated to keep Sorrento’s promising cancer drug, Cynviloq, off the market in order to preserve Soon-Shiong’s personal financial interest in another competing drug.

Los Angeles Court Rejects Patrick Soon-Shiong’s Attempt to Avoid Sorrento Litigation Allowing Arbitration Case to Move Forward

SAN DIEGO, Oct.  09, 2019  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced the closing of its previously announced registered direct offering of 10,869,566 shares of its common stock and warrants to purchase up to 10,869,566 shares of its common stock, at a combined purchase price of $2.30 per share and related warrant. The net proceeds to Sorrento from this offering are expected to be approximately $23.3 million, after deducting the placement agent’s fees and other estimated offering expenses. Sorrento currently intends to use the net proceeds from the offering for the continued clinical development of its RTX and CD38 CAR-T programs and general research and development, working capital and general corporate purposes.

Sorrento Therapeutics Announces Closing of $25 Million Registered Direct Offering

Aurora Cannabis

Ngm Biopharmaceuticals Inc

Tough industry conditions and company-specific issues hit these stocks.

Why Aurora Cannabis, Sorrento Therapeutics, and NGM Biopharmaceuticals Slumped Today

SAN DIEGO, Oct.  07, 2019  (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases, today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase in a registered direct offering of 10,869,566 shares of its common stock and warrants to purchase up to 10,869,566 shares of its common stock, at a combined purchase price of $2.30 per share and related warrant. The offering is expected to close on or about October 9, 2019, subject to the satisfaction of customary closing conditions.

Sorrento Therapeutics Announces $25 Million Registered Direct Offering

SAN DIEGO, Sept.  23, 2019  (GLOBE NEWSWIRE) -- Scilex Holding Company (Scilex), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE), announced that it has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission (the "SEC") relating to its proposed initial public offering of its common stock. The size and price range for the proposed offering have not yet been determined. The initial public offering is expected to commence after the completion of the SEC review process, subject to market and other conditions.

Scilex Holding Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

Sorrento Therapeutics (SRNE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sorrento Therapeutics (SRNE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Sorrento Therapeutics, Inc. (SRNE) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Moving Average Crossover Alert: Sorrento Therapeutics

PG&E

Pier 1 Imports

Find out which bad news sent these stocks lower.

Why PG&E, Pier 1 Imports, and Sorrento Therapeutics Slumped Today

Sorrento Therapeutics news for Friday concerning the company announcing a new equity offering has SRNE stock falling hard.
The post Sorrento Therapeutics News: SRNE Stock Tanks on Equity Offering appeared first on InvestorPlace.

Sorrento Therapeutics News: SRNE Stock Tanks on Equity Offering

Sorrento remains on track to execute its business plans in the 2H19.

Stacking The Deck: Henry Ji Is Setting The Stage For A Sorrento Therapeutics Breakout

Sorrento Therapeutics Inc. announced Wednesday that the Phase 1b study of its drug resinferatoxin is in progress and has generated positive data.

Sorrento Therapeutics Shares Move On RTX Trial Update

Sorrento Therapeutics, Inc. announced it's exploring the possibility of an initial public offering of its majority-owned subsidiary, Scilex Holding.

Sorrento Therapeutics Could IPO Its Scilex Unit

The biopharma stock is continuing to experience volatility today.

Why Sorrento Therapeutics Is Getting Crushed Today

Investors need to pay close attention to Sorrento (SRNE) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Sorrento (SRNE) Stock

Sorrento (SRNE) may provide update on progress of ZTlido on the first quarter earnings call.

What's in Store for Sorrento (SRNE) This Earnings Season?

Good news from a preclinical study is exciting investors about the potential for one of Sorrento's experimental drugs.

Why Sorrento Therapeutics Is Jumping Today

The early-stage biotech jumped without any significant news.

Here's Why Sorrento Therapeutics Soared 134% in March

In 2015, Sorrento Therapeutics sold one of its drugs to a Soon-Shiong company, NantPharma.

Sorrento Therapeutics Is Not Happy

News for Sorrento Therapeutics Inc Stock (SRNE)